Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma

References

• Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol. 2001;13:325–334.
   PubMed Web of Science ®Google Scholar
• Hui D, Proctor B, Donaldson J, et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma. 2010;51:1658–1667.
   PubMed Web of Science ®Google Scholar
• Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation-a population-based study of 1575 cases. Br J Haematol. 2004;124:151–159.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:498–505.
   PubMed Web of Science ®Google Scholar
• Zhao H, Guo L, Zhao H, et al. CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget. 2015;6:5022–5040.
   PubMedGoogle Scholar
• Calandra G, Bridger G, Fricker S. CXCR4 in clinical hematology. Curr Top Microbiol Immunol. 2010;341:173–191.
   PubMed Web of Science ®Google Scholar
• Middle S, Coupland SE, Taktak A, et al. Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Exp Hematol Oncol. 2015;4:10.
   PubMedGoogle Scholar
• Schmidt J, Federmann B, Schindler N, et al. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol. 2015;69:795–803.
   Web of Science ®Google Scholar
• Kim YR, Eom KS. Simultaneous inhibition of CXCR4 and VLA-4 exhibits combinatorial effect in overcoming stroma-mediated chemotherapy resistance in mantle cell lymphoma cells. Immune Netw. 2014;14:296–306.
   PubMedGoogle Scholar
• Han TT, Fan L, Li JY, et al. Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy. Cancer Biol Ther. 2014;15:3–9.
   PubMed Web of Science ®Google Scholar
• Menter T, Ernst M, Drachneris J, et al. Phenotype profiling of primary testicular diffuse large B-cell lymphomas. Hematol Oncol. 2014;32:72–81.
   PubMed Web of Science ®Google Scholar
• Moreno MJ, Bosch R, Dieguez-Gonzalez R, et al. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. J Pathol. 2015;235:445–455.
   PubMed Web of Science ®Google Scholar
• Chen J, Xu-Monette ZY, Deng L, et al. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget. 2015;6:5597–5614.
   PubMed Web of Science ®Google Scholar
• Majchrzak A, Witkowska M, Smolewski P. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance. Molecules. 2014;19:14304–14315.
   PubMed Web of Science ®Google Scholar
• Xu ZZ, Xia ZG, Wang AH, et al. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann Hematol. 2013;92:1351–1358.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumors: pathology and genetics of tumors of hematopoetic and lymphoid tissues. IARC Press; Lyon, France; 2001.
   Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015;14:207.
   PubMed Web of Science ®Google Scholar
• Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23:879–894.
   PubMed Web of Science ®Google Scholar
• Kallikourdis M, Trovato AE, Anselmi F, et al. The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse. Blood. 2013;122:666–673.
   PubMed Web of Science ®Google Scholar
• Brault L, Rovo A, Decker S, et al. CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia. Leukemia. 2014;28:566–576.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo Q, Zhao H, et al. Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome. Med Oncol. 2013;30:341.
   PubMed Web of Science ®Google Scholar
• de Lourdes PA, Amarante MK, Guembarovski RL, et al. CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target. Cell Mol Life Sci. 2015;72:1715–1723.
   PubMed Web of Science ®Google Scholar
• Sison EA, McIntyre E, Magoon D, et al. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol Cancer Res. 2013;11:1004–1016.
   PubMed Web of Science ®Google Scholar
• Chen Y, Jacamo R, Konopleva M, et al. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest. 2013;23:2395–2407.
   Google Scholar
• Mazur G, Butrym A, Kryczek I, et al. Decreased expression of CXCR4 chemokine receptor in bone marrow after chemotherapy in patients with non-hodgkin lymphomas is a good prognostic factor. PLoS One. 2014;9:e98194.
   PubMed Web of Science ®Google Scholar
• Shin HC, Seo J, Kang BW, et al. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. Korean J Intern Med. 2014;29:785–792.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Foon K, Takeshita AK, Zinzani PL. Novel therapies for aggressive B-cell lymphoma. Adv Hematol. 2012; 2012:302570
   PubMedGoogle Scholar
• Peng SB, Peek V, Zhai Y, et al. Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1α/CXCR4-mediated migration of epitheloid carcinoma cells. Mol Cancer Res. 2005;3:227–236.
   PubMed Web of Science ®Google Scholar
• Han Y, He T, Huang DR, et al. TNF-alpha mediates SDF-1 alpha-induced NF-kappa B activation and cytotoxic effects in primary astrocytes. J Clin Invest. 2001;108:425–435.
   PubMed Web of Science ®Google Scholar
• Soldevila G, Licona I, Salgado A, et al. Impaired chemokine-induced migration during T-cell development in the absence of Jak 3. Immunology. 2004;112:191–200.
   PubMed Web of Science ®Google Scholar
• Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005;8:179–183.
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Grau M, Lenze D, et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110:12420–12425.
   PubMed Web of Science ®Google Scholar
• Mathews Griner LA, Guha R, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA. 2014;111:2349–2354.
   PubMed Web of Science ®Google Scholar